Literature DB >> 10577683

Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecological cancer.

A Buchali1, S Koswig, S Dinges, P Rosenthal, J Salk, G Lackner, D Böhmer, L Schlenger, V Budach.   

Abstract

PURPOSE: Determination of the impact of the filling status of the organs at risk (bladder and rectum) on the uterus mobility and on their integral dose distribution in radiotherapy of gynaecological cancer.
METHODS: In 29 women suffering from cervical or endometrial cancer two CT scans were carried out for treatment planning, one with an empty bladder and rectum, the second one with bladder and rectum filled. The volumes of the organs at risk were calculated and in 14 patients, receiving a definitive radiotherapy, the position of the uterus within the pelvis was shown using multiplanar reconstructions. After generation of a 3D treatment plan the dose volume histograms were compared for empty and filled organs at risk.
RESULTS: The mobility for the corpus uteri with/without bladder and rectum filling was in median 7 mm (95%-confidence interval: 3-15 mm) in cranial/caudal direction and 4 mm (0-9 mm) in posterior/anterior direction. Likewise, cervical mobility was observed to be 4 mm (-1-6 mm) mm in cranial/caudal direction. A full bladder led to a mean reduction in organ dose in median from 94-87% calculated for 50% of the bladder volume (P < 0.05, Wilcoxon's matched-pairs signed-ranks test). For 66% of the bladder volume the dose could be reduced in median from 78 to 61% (P < 0.005) and for the whole bladder from 42 to 39% (P < 0.005), respectively. No significant contribution of the filling status of the rectum to its integral dose burden was noticed.
CONCLUSIONS: Due to the mobility of the uterus increased margins between CTV and PTV superiorly, inferiorly, anteriorly and posteriorly of 15, 6 and 9 mm each, respectively, should be used. A full bladder is the prerequisite for an integral dose reduction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577683     DOI: 10.1016/s0167-8140(99)00068-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter.

Authors:  Charles W Scarantino; Bradley R Prestidge; Mitchel S Anscher; Carolyn R Ferree; William T Kearns; Robert D Black; Natasha G Bolick; Gloria P Beyer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

Review 2.  In vivo dosimetry: trends and prospects for brachytherapy.

Authors:  G Kertzscher; A Rosenfeld; S Beddar; K Tanderup; J E Cygler
Journal:  Br J Radiol       Date:  2014-07-08       Impact factor: 3.039

3.  An assessment of interfractional bladder, rectum and vagina motion in postoperative cervical cancer based on daily cone-beam computed tomography.

Authors:  Xin Wang; Min Yu; Jin Wang; Renming Zhong; Yali Shen; Yaqin Zhao; Zhiping Li; Sen Bai; Feng Xu
Journal:  Mol Clin Oncol       Date:  2015-12-10

4.  Dosimetric comparison of MRI-based HDR brachytherapy and stereotactic radiotherapy in patients with advanced cervical cancer: A virtual brachytherapy study.

Authors:  Bretislav Otahal; Martin Dolezel; Jakub Cvek; Ondrej Simetka; Jaroslav Klat; Lukas Knybel; Lukas Molenda; Eva Skacelikova; Ales Hlavka; David Feltl
Journal:  Rep Pract Oncol Radiother       Date:  2014-05-01

5.  Prospective Validation of a High Dimensional Shape Model for Organ Motion in Intact Cervical Cancer.

Authors:  Casey W Williamson; Garrett Green; Sonal S Noticewala; Nan Li; Hanjie Shen; Florin Vaida; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-08-22       Impact factor: 7.038

Review 6.  Whole pelvic intensity-modulated radiotherapy for gynecological malignancies: A review of the literature.

Authors:  Rockne Hymel; Guy C Jones; Charles B Simone
Journal:  Crit Rev Oncol Hematol       Date:  2015-01-03       Impact factor: 6.312

7.  How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients.

Authors:  Santam Chakraborty; M Geetha; Sampada Dessai; Vijay M Patil
Journal:  Ecancermedicalscience       Date:  2014-11-20

8.  Prospective evaluation of the setup errors and its impact on safety margin for cervical cancer pelvic conformal radiotherapy.

Authors:  Avinash Badajena; Vijay Parshuram Raturi; Kirti Sirvastava; Hidehiro Hojo; Hajime Ohyoshi; Yanping Bei; Toshiya Rachi; Chen-Ta Wu; Taku Tochinai; Masayuki Okumura; Haiqin Zhang; Hirotaki Kouta; Pragya Verma; Geeta Singh; Abhishek Anand; Anjali Sachan
Journal:  Rep Pract Oncol Radiother       Date:  2020-02-22

9.  Effect of bladder distension on dosimetry of organs at risk in computer tomography based planning of high-dose-rate intracavitary brachytherapy for cervical cancer.

Authors:  Niladri B Patra; Kazi S Manir; Swapnendu Basu; Jyotirup Goswami; Apurba K Kabasi; Shyamal K Sarkar
Journal:  J Contemp Brachytherapy       Date:  2013-03-29

10.  Optimum organ volume ranges for organs at risk dose in cervical cancer intracavitary brachytherapy.

Authors:  Zahra Siavashpour; Mahmoud Reza Aghamiri; Ramin Jaberi; Hamid Reza Dehghan Manshadi; Reza Ghaderi; Christian Kirisits
Journal:  J Contemp Brachytherapy       Date:  2016-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.